Literature DB >> 11191881

Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds.

W F Li1, L G Costa, R J Richter, T Hagen, D M Shih, A Tward, A J Lusis, C E Furlong.   

Abstract

Human paraoxonase (PON1) is a polymorphic, high-density lipoprotein (HDL)-associated esterase that hydrolyzes the toxic metabolites of several organophosphorus (OP) insecticides and nerve agents. The activity polymorphism is determined by a Gln/Arg (Q/R) substitution at position 192. Injection of purified PON1 protects animals from OP poisoning. In the present study, we investigated the in-vivo function of PON1 for detoxifying organophosphorus insecticides in PON1-knockout mice that were challenged via dermal exposure with diazoxon, diazinon and paraoxon. PON1-knockout mice were extremely sensitive to diazoxon. Doses (2 and 4 mg/kg) that caused no cholinesterase (ChE) inhibition in wild-type mice were lethal to the knockout mice, which also showed slightly increased sensitivity to the parent compound diazinon. Surprisingly, these knockout mice did not show increased sensitivity to paraoxon. In-vitro assays indicated that the PON1R192 isoform hydrolyzed diazoxon less rapidly than did the PON1Q192 isoform. In-vivo analysis, where PON1-knockout mice received the same amount of either PON1(192) isoform via intraperitoneal (i.p.) injection 4 h prior to exposure, showed that both isoforms provided a similar degree of protection against diazoxon, while PON1R192 conferred better protection against chlorpyrifos-oxon than PON1Q192. Injection of purified rabbit PON1 or either human PON1(192) isoform did not protect PONI-knockout mice from paraoxon toxicity, nor did over-expression of the human PON1R192 transgene in wild-type mice. Kinetic analysis of the two human PON1(192) isoforms revealed that the catalytic efficiency (Vmax/Km) determines the in-vivo efficacy of PON1 for organophosphorus detoxication. The results indicate that PON1 plays a major role in the detoxication of diazoxon and chlorpyrifos oxon but not paraoxon.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11191881     DOI: 10.1097/00008571-200012000-00002

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  70 in total

1.  Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization.

Authors:  Amir Aharoni; Leonid Gaidukov; Shai Yagur; Lilly Toker; Israel Silman; Dan S Tawfik
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

2.  Prenatal exposure to organophosphate pesticides, maternal paraoxonase 1 genotype, and childhood neurodevelopment at 24 months of age in Shandong, China.

Authors:  Yiwen Wang; Yan Zhang; Lin Ji; Yijun Zhou; Rong Shi; Michihiro Kamijima; Jun Ueyama; Yu Gao; Ying Tian
Journal:  Environ Sci Pollut Res Int       Date:  2019-11-25       Impact factor: 4.223

Review 3.  Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Authors:  Daniel Seung Kim; Judit Marsillach; Clement E Furlong; Gail P Jarvik
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 4.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

5.  Paraoxonase 1 (PON1) modulates the toxicity of mixed organophosphorus compounds.

Authors:  Karen L Jansen; Toby B Cole; Sarah S Park; Clement E Furlong; Lucio G Costa
Journal:  Toxicol Appl Pharmacol       Date:  2009-02-09       Impact factor: 4.219

Review 6.  Paraoxonase-2 (PON2) in brain and its potential role in neuroprotection.

Authors:  Lucio G Costa; Rian de Laat; Khoi Dao; Claudia Pellacani; Toby B Cole; Clement E Furlong
Journal:  Neurotoxicology       Date:  2013-09-04       Impact factor: 4.294

7.  A pilot study assessing the association between paraoxonase 1 gene polymorphism and prostate cancer.

Authors:  Nihat Uluocak; Doğan Atılgan; Bekir Süha Parlaktaş; Fikret Erdemir; Ömer Ateş
Journal:  Turk J Urol       Date:  2017-07-31

8.  Paraoxonase 1 (PON1) status and substrate hydrolysis.

Authors:  Rebecca J Richter; Gail P Jarvik; Clement E Furlong
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-13       Impact factor: 4.219

9.  Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease.

Authors:  Angelika D Manthripragada; Sadie Costello; Myles G Cockburn; Jeff M Bronstein; Beate Ritz
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

10.  Human paraoxonase 1 hydrolysis of nanomolar chlorpyrifos-oxon concentrations is unaffected by phenotype or Q192R genotype.

Authors:  R Hunter Coombes; Edward C Meek; Mary Beth Dail; Howard W Chambers; Janice E Chambers
Journal:  Toxicol Lett       Date:  2014-08-02       Impact factor: 4.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.